We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Eisai Expands into Canada

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. has announces the establishment of Eisai Limited in Canada, the world’s ninth largest pharmaceutical market.

As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.

“Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region”

“Eisai’s entrance into Canada supports our strategy to strengthen our business operations and presence in North America as we prepare for future expansion in this region,” said Hajime Shimizu, Chairman and CEO, Eisai Inc. “Most importantly, this new subsidiary will enable Eisai to introduce many of its first-in-class products to people living in Canada who currently do not have access to these treatments, further supporting Eisai’s human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide.”